Oryzon Genomics SA
- Company typePublic
- Founded2000
- HeadquartersBarcelona, Spain
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
Oryzon Genomics SA firmographics
Firmographics- Name
- Oryzon Genomics SA
- Legal name
- ORYZON GENOMICS S.A.
- Website
- https://oryzon.com
- Company type
- Public
- Founded year
- 2000
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
Where Oryzon Genomics SA is headquartered
LocationHeadquarters
- HQ city
- Barcelona
- HQ country
- Spain
- HQ region
- Europe
Offices3 records
Markets served
Oryzon Genomics SA business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Others
Revenue model
- Pharmaceutical Development: Pre-revenue clinical stage biopharmaceutical company developing epigenetic therapies. Revenue expected from future drug approvals and commercialization.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
Oryzon Genomics SA product offering
Product offeringCore offering
Oryzon Genomics develops small-molecule epigenetic therapeutics targeting LSD1 and HDAC6 enzymes for cancer and central nervous system disorders. The pipeline is anchored by two clinical-stage covalent LSD1 inhibitors—Iadademstat (ORY-1001) in oncology indications and Vafidemstat (ORY-2001) in CNS indications—and one preclinical HDAC6 inhibitor (ORY-4001) for neurological diseases. The company has no commercialized products and currently operates as a clinical-stage developer preparing assets for out-licensing or co-development with larger pharmaceutical partners.
Product overview
Oryzon Genomics SA is a clinical-stage biopharmaceutical company developing epigenetic medicines for oncology and CNS disorders. The company has two main LSD1 inhibitors in clinical development: iadademstat (ORY-1001) for hematological malignancies including acute myeloid leukemia, and vafidemstat (ORY-2001) for psychiatric and neurological disorders. Additionally, ORY-4001 is a selective HDAC6 inhibitor in preclinical development for neurological diseases.
Differentiator
Problem solved
Functional benefit
Products and services
- Iadademstat (ORY-1001)
- Vafidemstat (ORY-2001)
- ORY-4001
Quantifiable outcome
- 100% overall response rate in first-line AML patients with iadademstat
- +3 more outcomes
Companies that use Oryzon Genomics SA
Customer profileNamed customers4 records
Segments2 records
Ideal customer profiles2 records
Oryzon Genomics SA technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Oryzon Genomics SA partnerships and signals
Strategic signalPartnerships
Seven partnerships are on record, tiered minor and core.
- Yale UniversityminorInvestigator-initiated Phase Ib trial evaluating iadademstat with radiotherapy and atezolizumab for extensive stage small cell lung cancer. Trial sponsored and conducted by Yale University.
- Medical College of WisconsinminorInvestigator-initiated Phase I trial evaluating iadademstat with azacitidine in myelodysplastic syndrome. Principal Investigator: Dr. Guru Subramanian Guru Murthy.
- National Cancer Institute (NCI)coreCRADA agreement for clinical development of iadademstat. NCI-sponsored Phase I trial of iadademstat with venetoclax and azacitidine in first-line AML. Principal Investigator: Dr. Natalie Galanina. Expected to recruit 45 patients.
- Oregon Health & Science University (OHSU) Knight Cancer InstitutecoreInvestigator-initiated Phase I study of iadademstat with venetoclax and azacitidine in first-line AML. Principal Investigator: Dr. Curtis Lachowiez.
- Fox Chase Cancer CenterminorCollaborative Phase II trial of iadademstat with paclitaxel in platinum-refractory/relapsed small cell lung cancer and high-grade extrapulmonary neuroendocrine tumors.
- European partners (BRAVE Project)minorEU-funded BRAVE Project evaluating iadademstat role in cancer immunotherapy. Collaboration with Danish and European partners to assess efficacy in combination with checkpoint inhibitors and vaccines in solid tumors over two years.
- Memorial Sloan Kettering Cancer CentercoreNCI-sponsored Phase I/II trial of iadademstat with immune checkpoint inhibitors in first-line metastatic small cell lung cancer. Principal Investigator: Dr. Charles Rudin.
Scale indicators9 records
Recent moves7 records
Expansion highlights6 records
Oryzon Genomics SA competitors and assessment
Company assessmentDirect peers
- Epizyme: Clinical-stage epigenetic oncology company developing EZH2 inhibitors (TAZVERIK) and other chromatin-targeting therapies. Comparable to Oryzon as a small-cap, clinical-stage epigenetic drug developer; acquired by Ipsen in 2022.
- Sage Therapeutics: Clinical-stage CNS biopharmaceutical company developing novel therapeutics for depression and other brain disorders. Comparable to Oryzon's vafidemstat as a small-cap, CNS-focused clinical-stage biotech with a single platform approach to CNS indications.
- Karuna Therapeutics: CNS-focused clinical-stage biotech with late-stage assets in schizophrenia and other psychiatric indications. Most directly comparable to Oryzon's vafidemstat CNS franchise, particularly for negative symptoms and BPD-adjacent indications; acquired by Bristol-Myers Squibb in 2024.
- Imago BioSciences: Clinical-stage developer of LSD1 inhibitors for myeloid malignancies and other diseases. Most direct mechanistic peer to Oryzon's iadademstat; acquired by Merck in 2023 for approximately $1.35B, validating the strategic value of selective LSD1 programs in this space.
Emerging players
- Constellation Pharmaceuticals: Clinical-stage developer of epigenetic drugs for cancer and inflammatory diseases, including EZH2 and other chromatin-modulating targets. Closely analogous business model to Oryzon's clinical-stage epigenetic approach; acquired by MorphoSys in 2021.
- BioXcel Therapeutics: Clinical-stage biopharmaceutical company applying AI to identify and develop transformative medicines in immuno-oncology and neuroscience. Comparable to Oryzon's vafidemstat given its CNS focus and small-cap clinical-stage profile.
- Aprea Therapeutics: Clinical-stage oncology company developing small-molecule therapies targeting the p53 pathway in hematologic malignancies and solid tumors. Comparable to Oryzon's iadademstat given shared focus on AML and small-molecule epigenetic/mechanism-targeted oncology drug development.
- GlycoMimetics: Clinical-stage company developing glycobiology-based therapies for AML and other hematologic malignancies. Comparable to Oryzon's iadademstat as a small-cap AML-focused clinical-stage biotech; acquired by Innovent Biologics in 2023.
Broad incumbents
- Acadia Pharmaceuticals: Established CNS-focused biopharmaceutical company commercializing therapies for Parkinson's disease psychosis, Rett syndrome, and other CNS disorders. Broader incumbent comparable to Oryzon's CNS franchise given overlap in neuropsychiatric indications and CNS commercial know-how.
Regional players
- Galapagos NV: European clinical-stage biopharmaceutical company developing small-molecule therapies, with historical focus on inflammation and oncology. Comparable to Oryzon as a publicly listed European clinical-stage biotech of similar size and capital structure profile.
Market position
Strengths5 records
Weaknesses4 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
Oryzon Genomics SA social profiles
Digital presenceOryzon Genomics SA financial estimates
Financial estimateRevenue estimate
Valuation estimate
Oryzon Genomics SA leadership team
Management profileNumber of profiles
Profiles15 records
Oryzon Genomics SA funding detail
Funding detailFunding overview
Funding rounds29 records
Investors13 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Oryzon Genomics SA M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Oryzon Genomics SA
What does Oryzon Genomics SA do?
Oryzon Genomics develops small-molecule epigenetic therapeutics targeting LSD1 and HDAC6 enzymes for cancer and central nervous system disorders. The pipeline is anchored by two clinical-stage covalent LSD1 inhibitors—Iadademstat (ORY-1001) in oncology indications and Vafidemstat (ORY-2001) in CNS indications—and one preclinical HDAC6 inhibitor (ORY-4001) for neurological diseases. The company has no commercialized products and currently operates as a clinical-stage developer preparing assets for out-licensing or co-development with larger pharmaceutical partners.
Is Oryzon Genomics SA a public or private company?
Oryzon Genomics SA is a public company. It is classified as public and is currently operating.
When was Oryzon Genomics SA founded?
Oryzon Genomics SA was founded in 2000. It employs 11 to 50 people.
Where is Oryzon Genomics SA based?
Oryzon Genomics SA is headquartered in Barcelona, Spain, in the Europe region.
How does Oryzon Genomics SA make money?
One revenue line is on record: pharmaceutical Development.
Who are Oryzon Genomics SA's main competitors?
Direct peers on record are Epizyme, Sage Therapeutics, Karuna Therapeutics and Imago BioSciences. Emerging players are Constellation Pharmaceuticals, BioXcel Therapeutics, Aprea Therapeutics and GlycoMimetics. Acadia Pharmaceuticals is listed as a broad incumbent. Galapagos NV is listed as a regional player.
Does Oryzon Genomics SA have an API?
No public API is recorded for Oryzon Genomics SA.